Determination and pharmacokinetic study of AZD‐3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer

BACKGROUND: AZD‐3759 is a new, potent, oral, active central nervous system‐penetrant EGFR inhibitor. Despite promising clinical activity among patients pretreated and never treated with EGFR‐tyrosine kinase inhibitors, no time saving pharmacokinetic study method has been reported in an animal model....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Wu, Qingjun, Hua, Ailian, Sun, Yaoguang, Ma, Chao, Tian, Wenxin, Huang, Chuan, Yu, Hanbo, Jiao, Peng, Wang, Shuanghu, Tong, Hongfeng, Qiu, Weiwen
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6209780/
https://ncbi.nlm.nih.gov/pubmed/30252204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12843
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados